Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

Complete title: A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patient with Unresectable Hepatocellular Carcinoma (HCC)

Research Study Number 20111617
 
Principal Investigator William Harris
 
Phase III

Research Study Description

The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20111617
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Gastrointestinal Cancer; Liver Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials